indazoles has been researched along with arq 197 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
Bottaro, DP; Cecchi, F; Chen, AP; Do, KT; Doroshow, JH; Jeong, W; Johnson, BC; Kummar, S; Lee, YH; Navas, T; Parchment, RE; Park, SR; Rubinstein, L; Srivastava, AK; Voth, AR; Wright, JJ | 1 |
1 review(s) available for indazoles and arq 197
Article | Year |
---|---|
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
1 trial(s) available for indazoles and arq 197
Article | Year |
---|---|
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatocyte Growth Factor; Humans; Indazoles; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Pyrrolidinones; Quinolines; Sulfonamides; Vascular Endothelial Growth Factor A | 2021 |